Moberg Pharma AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was SEK 0.207 million. Net loss was SEK 15.71 million compared to net income of SEK 7.49 million a year ago.

Basic loss per share from continuing operations was SEK 2.1 compared to SEK 3.8 a year ago. Diluted loss per share from continuing operations was SEK 2.1 compared to SEK 3.8 a year ago. Basic loss per share was SEK 2.1 compared to basic earnings per share of SEK 1.7 a year ago.

Diluted loss per share was SEK 2.1 compared to diluted earnings per share of SEK 1.7 a year ago.